Browsing Tag
bispecific antibodies
4 posts
Antengene–UCB autoimmune deal: Why the $1.1bn ATG-201 partnership could reshape B-cell targeting therapies
Antengene licenses ATG-201 to UCB in a $1.1B autoimmune drug deal. Discover why bispecific antibodies are becoming the next frontier in immunology.
Can Epcoritamab plus R2 become the new second-line standard in follicular lymphoma after Genmab’s Phase 3 success?
Genmab’s Epcoritamab plus R2 combo cut FL relapse risk by 79% in Phase 3. Find out why this bispecific therapy may reshape second-line treatment.
XOMA Royalty completes LAVA Therapeutics acquisition in push to strengthen bispecific antibody pipeline
Find out how XOMA Royalty’s acquisition of LAVA Therapeutics strengthens its oncology royalty portfolio and expands its partnered bispecific antibody programs.
Innovent Biologics showcases promising preclinical data at AACR 2024
In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for…